Table 1: Characteristics of the Patients at Baseline
|
Characteristic |
Treatment |
||
|
Group 1 Standard of care + tocilizumab (n = 54) |
Group 2 Standard of care + tocilizumab + remdesivir (n = 73) |
P value |
|
|
Average Age - median (IQR) |
63 (54.65) |
65 (52.65) |
0.0008 |
|
Ethnicity - No. (%) |
0.2 |
||
|
White or Caucasian |
3 (5) |
10 (14) |
|
|
Hispanic or Latino |
46 (85) |
51 (70) |
|
|
African American |
4 (7) |
7 (10) |
|
|
Other |
1 (2) |
5 (7) |
|
|
Sex -No. (%) |
0.3 |
||
|
Male |
29 (54) |
46 (63) |
|
|
Female |
25 (46) |
27 (37) |
|
|
Respiratory support received - No. (%) |
< 0.0001 |
||
|
Category 1† |
35 (65) |
14 (19) |
|
|
Category 2† |
12 (22) |
39 (53) |
|
|
Category 3† |
7 (13) |
20 (27) |
|
|
Previous coexisting disease - No. (%) |
|||
|
Obesity‡ |
25 (46) |
44 (61) |
0.2 |
|
Diabetes |
16 (30) |
29 (40) |
0.24 |
|
COPD |
3 (6) |
7 (10) |
0.5 |
|
CVD§ |
29 (54) |
55 (75) |
0.01 |
|
Reduced kidney function¶ |
24 (44) |
26 (36) |
0.3 |
|
Current smoker - No. (%) |
1 (2) |
10 (14) |
0.02 |
†Category 1: Nasal cannula, humidified nasal oxygen, simple face mask; Category 2: High flow, non-rebreather, BIPAP, CPAP; Category 3: ECMO, mechanical ventilation, PRVC/AC, APRV, assistance/control. When tested via Chi-square, group 2 has significantly more patients receiving higher levels of respiratory support (p < 0.0001); ‡Obesity was defined as a body mass index of 30 or greater; §Cardiovascular disease included heart failure, stroke, myocardial Infarction, peripheral artery disease, coronary artery disease, hyperlipidemia or hypertension; ¶Reduced kidney function was defined as an estimated glomerular filtration rate of less than 60 ml per minute per 1.73 m2.